XPH - SPDR S&P Pharmaceuticals ETF
|Ex-Dividend Date||Mar 22, 2021|
|Trading Day||April 13|
|Day's Range||47.81 - 48.38|
|52-Week Range||37.71 - 56.24|
The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the pharmaceuticals segment of a U.S. total market composite index. In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the index), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals segment of the S&P Total Market Index (S&P TMI).
|Asset Class |
|Inception Date |
Jun 19, 2006
|Ticker Symbol |
|Index Tracked |
S&P Pharmaceuticals Select Industry Index
Top 10 Holdings44.23% of assets
|Johnson & Johnson||JNJ||4.44%|
|Mar 22, 2021||$0.072||Mar 25, 2021|
|Dec 21, 2020||$0.054||Dec 24, 2020|
|Sep 21, 2020||$0.052||Sep 24, 2020|
|Jun 22, 2020||$0.067||Jun 25, 2020|
|Mar 23, 2020||$0.072||Mar 26, 2020|
|Dec 23, 2019||$0.071||Dec 27, 2019|
Sector ETF report for XPH
These seven healthcare stocks may represent robust long-term investments no matter how reforms in the sector may develop post-election. The post 7 Healthcare Stocks That Can Survive Massive Reform appea...
These funds could be the best ways for investors to tap the opportunity arising from the Bristol Myers-MyoKardia deal and will likely see smooth trading in the months to come.
President Trump signs executive orders aimed at lowering drug prices
CNBC's Meg Tirrell reports President Trump has signed four executive orders aimed at lowering drug prices. They include the U.S. allowing importation of prescription drugs from Canada and other countries.
President Donald Trump on Friday signed four executive orders aimed at lowering the high cost of prescription drugs in the United States in what would make sweeping changes to the prescription drug mark...
Where this top-rated financial advisor is finding opportunities in the market now
Hightower Treasury Partners CIO Richard Saperstein outlines the areas of the market where he currently sees opportunity.
The pharmaceutical industry is often a hotbed of takeover rumors.
What does the investment committee recommend in health care? #AskHalftime
The "Halftime Report" traders answer viewer questions in #AskHalftime.
In a market that has been steadily climbing despite impeachment proceedings against President Trump, a roller-coaster ride due to tariffs and a trade war with China, and generalized global uncertainty, ...
Mizuho: Smaller companies are leading the way in developing vaccines for infectious diseases
Mara Goldstein of Mizuho discusses the difficulty of developing a vaccine quickly during a virus outbreak, and which large and smaller biotech and drug companies investors should be focused on.
Robust results led to solid trading in pharma ETFs in a month.
Despite robust results, pharma ETFs have been trending downward in a month.
What to Expect From Big Pharma's Earnings
We expect solid results but will be listening for what a reduction in rebating means for sales growth at various firms, among other trends.
Consumer strong despite recession fears, says Nuveen's Stephanie Link
Stephanie Link of Nuveen and CNBC's Mike Santoli discuss the markets after the close on "Closing Bell."
Tech stocks facing regulations no matter the midterm outcome?
Hedge fund manager Jonathan Hoenig on the impact of the midterm elections on the markets.